Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1978 May;61(5):1196–1203. doi: 10.1172/JCI109035

Differences between Type I Autoimmune Inhibitors of Fibrin Stabilization in Two Patients with Severe Hemorrhagic Disorder

S Lopaciuk 1,2,3,4,5,6, K Bykowska 1,2,3,4,5,6, J M McDonagh 1,2,3,4,5,6, R P McDonagh 1,2,3,4,5,6, W J Yount 1,2,3,4,5,6, C R Fuller 1,2,3,4,5,6, L Cooperstein 1,2,3,4,5,6, A Gray Jr 1,2,3,4,5,6, L Lorand 1,2,3,4,5,6
PMCID: PMC372640  PMID: 96136

Abstract

Inhibitors of fibrin stabilization of apparently autoimmune origin, found in two severely bleeding unrelated patients (W. G. and G. A.), were compared with regard to their biological target specificities, potencies and immunological characteristics. Both interfered only with the activation of fibrin stabilizing factor (coagulation Factor XIII) and, while totally preventing the conversion of this zymogen to the functional transamidating enzyme, fibrinoligase (Factor XIIIa), they showed very little inhibition toward the enzyme itself. Thus, according to the classification of Lorand concerning biological specificities, both can be characterized as Type I inhibitors of fibrin stabilization. Potencies of the two inhibitors were quite similar when measured in conjunction with the plasma zymogen, but they differed remarkably in tests with platelet Factor 13. The inhibitor of patient W. G. prevented the activation of the zymogen from platelets, but that of G. A. had no effect on the platelet factor. It may therefore be concluded that the inhibitor of W. G. is directed exclusively against the a subunit which is a common constituent of plasma as well as platelet factors. The inhibitor of G. A., however, must be targeted against determinants uniquely characteristic for the ab ensemble of the plasma zymogen including the b subunit. On the basis of this difference in target specificity, the inhibitor of W. G. is designated as Type I-1 and that of G. A. as Type I-2.

The inhibitors of both patients were isolated as immunoglobulins, and neutralization tests revealed that the antibody of W. G. comprised mainly heavy chains of the IgG1 and light chains of the κ class. The antibody of G. A. proved to be considerably more heterogeneous and contained IgG1 and IgG3 heavy chains as well as κ- and λ-light chains.

The finding that the antibody of W. G. inhibited conversion of platelet Factor 13 and also its thrombinmodified form, but had no effect on the thrombin and Ca2+-activated factor, is an indication that antigenic determinants existing both on the native zymogen and on its hydrolytically modified form become buried in the Ca2+-dependent step of activation. This is clear evidence for the occurrence of a significant conformational change in the protein structure attendant to the process of unmasking of its enzymic activity.

Full text

PDF
1196

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cannat A., Seligmann M. Possible induction of antinuclear antibodies by isoniazid. Lancet. 1966 Jan 22;1(7430):185–187. doi: 10.1016/s0140-6736(66)90704-5. [DOI] [PubMed] [Google Scholar]
  2. Chung S. I., Lewis M. S., Folk J. E. Relationships of the catalytic properties of human plasma and platelet transglutaminases (activated blood coagulation factor XIII) to their subunit structures. J Biol Chem. 1974 Feb 10;249(3):940–950. [PubMed] [Google Scholar]
  3. Cooke R. D., Holbrook J. J. The calcium-induced dissociation of human plasma clotting factor XIII. Biochem J. 1974 Jul;141(1):79–84. doi: 10.1042/bj1410079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Corran P. H., Waley S. G. The reaction of penicillin with proteins. Biochem J. 1975 Aug;149(2):357–364. doi: 10.1042/bj1490357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Curtis C. G., Brown K. L., Credo R. B., Domanik R. A., Gray A., Stenberg P., Lorand L. Calcium-dependent unmasking of active center cysteine during activation of fibrin stabilizing factor. Biochemistry. 1974 Aug 27;13(18):3774–3780. doi: 10.1021/bi00715a024. [DOI] [PubMed] [Google Scholar]
  6. Curtis C. G., Lorand L. Fibrin-stabilizing factor (factor XIII). Methods Enzymol. 1976;45:177–191. doi: 10.1016/s0076-6879(76)45018-8. [DOI] [PubMed] [Google Scholar]
  7. Dash C. H. Penicillin allergy and the cephalosporins. J Antimicrob Chemother. 1975;1(3 Suppl):107–118. doi: 10.1093/jac/1.suppl_3.107. [DOI] [PubMed] [Google Scholar]
  8. Graham J. E., Yount W. J., Roberts H. R. Immunochemical characterization of a human antibody to factor XIII. Blood. 1973 May;41(5):661–669. [PubMed] [Google Scholar]
  9. HOREJSI J., SMETANA R. The isolation of gamma globulin from blood-serum by rivanol. Acta Med Scand. 1956 Jun 30;155(1):65–70. doi: 10.1111/j.0954-6820.1956.tb14351.x. [DOI] [PubMed] [Google Scholar]
  10. LORAND L. Fibrin clots. Nature. 1950 Oct 21;166(4225):694–695. doi: 10.1038/166694a0. [DOI] [PubMed] [Google Scholar]
  11. LORAND L., KONISHI K. ACTIVATION OF THE FIBRIN STABILIZING FACTOR OF PLASMA BY THROMBIN. Arch Biochem Biophys. 1964 Apr;105:58–67. doi: 10.1016/0003-9861(64)90235-8. [DOI] [PubMed] [Google Scholar]
  12. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  13. Laki K., Lóránd L. On the Solubility of Fibrin Clots. Science. 1948 Sep 10;108(2802):280–280. doi: 10.1126/science.108.2802.280. [DOI] [PubMed] [Google Scholar]
  14. Lorand L., Campbell-Wilkes L. K., Cooperstein L. A filter paper assay for transamidating enzymes using radioactive amine substrates. Anal Biochem. 1972 Dec;50(2):623–631. doi: 10.1016/0003-2697(72)90074-7. [DOI] [PubMed] [Google Scholar]
  15. Lorand L., Campbell L. K., Robertson B. J. Enzymatic coupling of isoniazid to proteins. Biochemistry. 1972 Feb 1;11(3):434–438. doi: 10.1021/bi00753a021. [DOI] [PubMed] [Google Scholar]
  16. Lorand L. Fibrinoligase: the fibrin-stabilizing factor system of blood plasma. Ann N Y Acad Sci. 1972 Dec 8;202:6–30. doi: 10.1111/j.1749-6632.1972.tb16319.x. [DOI] [PubMed] [Google Scholar]
  17. Lorand L., Gray A. J., Brown K., Credo R. B., Curtis C. G., Domanik R. A., Stenberg P. Dissociation of the subunit structure of fibrin stabilizing factor during activation of the zymogen. Biochem Biophys Res Commun. 1974 Feb 27;56(4):914–922. doi: 10.1016/s0006-291x(74)80275-5. [DOI] [PubMed] [Google Scholar]
  18. Lorand L., Maldonado N., Fradera J., Atencio A. C., Robertson B., Urayama T. Haemorrhagic syndrome of autoimmune origin with a specific inhibitor against fibrin stabilizing factor (factor XIII). Br J Haematol. 1972 Jul;23(1):17–27. doi: 10.1111/j.1365-2141.1972.tb03455.x. [DOI] [PubMed] [Google Scholar]
  19. Lorand L., Urayama T., De Kiewiet J. W., Nossel H. L. Diagnostic and genetic studies on fibrin-stabilizing factor with a new assay based on amine incorporation. J Clin Invest. 1969 Jun;48(6):1054–1064. doi: 10.1172/JCI106061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  21. McDonagh J., Messel H., McDonagh R. P., Jr, Murano G., Blombäck B. Molecular weight analysis of fibrinogen and fibrin chains by an improved sodium dodecyl sulfate gel electrophoresis method. Biochim Biophys Acta. 1972 Jan 26;257(1):135–142. doi: 10.1016/0005-2795(72)90262-0. [DOI] [PubMed] [Google Scholar]
  22. Mcdonagh J., Waggoner W. G., Hamilton E. G., Hindenbach B., Mcdonagh R. P. Affinity chromatography of human plasma and platelet factor XIII on organomercurial agarose. Biochim Biophys Acta. 1976 Oct 28;446(2):345–357. doi: 10.1016/0005-2795(76)90002-7. [DOI] [PubMed] [Google Scholar]
  23. Pike I. M., Yount W. J., Puritz E. M., Roberts H. R. Immunochemical characterization of a monoclonal G4,lambda human antibody to factor IX. Blood. 1972 Jul;40(1):1–10. [PubMed] [Google Scholar]
  24. Schwartz M. L., Pizzo S. V., Hill R. L., McKee P. A. Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem. 1973 Feb 25;248(4):1395–1407. [PubMed] [Google Scholar]
  25. Schwartz M. L., Pizzo S. V., Hill R. L., McKee P. A. The subunit structures of human plasma and platelet factor XIII (fibrin-stabilizing factor). J Biol Chem. 1971 Sep 25;246(18):5851–5854. [PubMed] [Google Scholar]
  26. Takagi T., Doolittle R. F. Amino acid sequence studies on factor XIII and the peptide released during its activation by thrombin. Biochemistry. 1974 Feb 12;13(4):750–756. doi: 10.1021/bi00701a018. [DOI] [PubMed] [Google Scholar]
  27. Tipper D. J., Strominger J. L. Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine. Proc Natl Acad Sci U S A. 1965 Oct;54(4):1133–1141. doi: 10.1073/pnas.54.4.1133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Wise E. M., Jr, Park J. T. Penicillin: its basic site of action as an inhibitor of a peptide cross-linking reaction in cell wall mucopeptide synthesis. Proc Natl Acad Sci U S A. 1965 Jul;54(1):75–81. doi: 10.1073/pnas.54.1.75. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES